Sutent
(sunitinib)Dosage & Administration
GIST and Advanced RCC:
Adjuvant Treatment of RCC:
pNET:
Sutent Prescribing Information
Hepatotoxicity may be severe, and in some cases, fatal. Monitor hepatic function and interrupt, dose reduce, or discontinue SUTENT as recommended [see Warnings and Precautions (5.1)].
Gastrointestinal Stromal Tumor
SUTENT is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Advanced Renal Cell Carcinoma
SUTENT is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC).
Adjuvant Treatment of Renal Cell Carcinoma
SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
Advanced Pancreatic Neuroendocrine Tumors
SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
Recommended Dosage for GIST and Advanced RCC
The recommended dosage of SUTENT for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. SUTENT may be taken with or without food.
Recommended Dosage for Adjuvant Treatment of RCC
The recommended dosage of SUTENT for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. SUTENT may be taken with or without food.
Recommended Dosage for pNET
The recommended dosage of SUTENT for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. SUTENT may be taken with or without food.
Dosage Modifications for Adverse Reactions
To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of SUTENT for adverse reactions.
| Indications | GIST | RCC | pNET | |
|---|---|---|---|---|
| Advanced RCC | Adjuvant RCC | |||
First dose reduction | 37.5 mg once daily | 37.5 mg once daily | 37.5 mg once daily | 25 mg once daily |
Second dose reduction | 25 mg once daily | 25 mg once daily | NA | NA |
| Adverse Reaction | Severity | Dosage Modifications for SUTENT |
|---|---|---|
Hepatotoxicity [see Warnings and Precautions (5.1)] | Grade 3 |
|
Grade 4 |
| |
Cardiovascular events [see Warnings and Precautions (5.2)] | Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) |
|
Clinically manifested congestive heart failure (CHF) |
| |
Hypertension [see Warnings and Precautions (5.4)] | Grade 3 |
|
Grade 4 |
| |
Hemorrhagic events [see Warnings and Precautions (5.5)] | Grade 3 or 4 |
|
Thrombotic microangiopathy [see Warnings and Precautions (5.7)] | Any Grade |
|
Proteinuria or Nephrotic syndrome [see Warnings and Precautions (5.8)] | 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome |
|
Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions |
| |
Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions (5.9)] | Any Grade |
|
Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10)] | Any Grade |
|
Osteonecrosis of the jaw [see Warnings and Precautions (5.13)] | Any Grade |
|
Impaired wound healing [see Warnings and Precautions (5.14)] | Any Grade |
|
Dosage Modification for Drug Interactions
Strong CYP3A4 Inhibitors
Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of SUTENT with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for SUTENT to a minimum dosage as follows [see Drug Interactions (7.1)]:
- •
- GIST and RCC: 37.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2)
- •
- pNET: 25 mg orally once daily
Strong CYP3A4 Inducers
Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of SUTENT with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for SUTENT to a maximum dosage as follows:
- •
- GIST and RCC: 87.5 mg orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2)
- •
- pNET: 62.5 mg orally once daily
If the dose of SUTENT is increased, monitor patients carefully for adverse reactions [see Drug Interactions (7.1)].
Dosage Modification for End-Stage Renal Disease Patients on Hemodialysis
No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology (12.3)].
Capsules, hard gelatin:
- •
- 12.5 mg sunitinib: orange cap and orange body, printed with white ink "Pfizer" on the cap and "STN 12.5 mg" on the body.
- •
- 25 mg sunitinib: caramel cap and orange body, printed with white ink "Pfizer" on the cap and "STN 25 mg" on the body.
- •
- 37.5 mg sunitinib: yellow cap and yellow body, printed with black ink "Pfizer" on the cap and "STN 37.5 mg" on the body.
- •
- 50 mg sunitinib: caramel top and caramel body, printed with white ink "Pfizer" on the cap and "STN 50 mg" on the body.
Pregnancy
Risk Summary
Based on animal reproduction studies and its mechanism of action, SUTENT can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolethality, craniofacial and skeletal malformations) at 5.5 and 0.3 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the recommended daily doses (RDD) of 50 mg, respectively (see Data). Advise females of reproductive potential of the potential risk to a fetus.
The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Animal Data
In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Embryolethality was observed at 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg).
In embryo-fetal developmental toxicity studies, oral sunitinib was administered to pregnant rats (0.3, 1.5, 3, 5 mg/kg/day) and rabbits (0.5, 1, 5, 20 mg/kg/day) during the period of organogenesis. In rats, embryolethality and skeletal malformations of the ribs and vertebrae were observed at the dose of 5 mg/kg/day (approximately 5.5 times the combined AUC in patients administered the RDD of 50 mg). No adverse fetal effects were observed in rats at doses ≤3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg). In rabbits, embryolethality was observed at 5 mg/kg/day (approximately 3 times the combined AUC in patients administered the RDD of 50 mg), and craniofacial malformations (cleft lip and cleft palate) were observed at ≥1 mg/kg/day (approximately 0.3 times the combined AUC in patients administered the RDD of 50 mg).
Sunitinib (0.3, 1, 3 mg/kg/day) was evaluated in a pre- and postnatal development study in pregnant rats. Maternal body weight gains were reduced during gestation and lactation at doses ≥1 mg/kg/day (approximately 0.5 times the combined AUC in patients administered the RDD of 50 mg). At 3 mg/kg/day (approximately 2 times the combined AUC in patients administered the RDD of 50 mg), reduced neonate body weights were observed at birth and persisted in the offspring of both sexes during the preweaning period and in males during postweaning period. No adverse developmental effects were observed at doses ≤1 mg/kg/day.
Lactation
There is no information regarding the presence of sunitinib and its metabolites in human milk. Sunitinib and its metabolites were excreted in rat milk at concentrations up to 12-fold higher than in plasma (see Data). Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with SUTENT and for at least 4 weeks after the last dose.
Data
Animal Data
In lactating female rats administered 15 mg/kg, sunitinib and its metabolites were excreted in milk at concentrations up to 12-fold higher than in plasma.
Females and Males of Reproductive Potential
SUTENT can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].
Pregnancy Testing
Verify pregnancy status of females of reproductive potential prior to initiating treatment with SUTENT.
Contraception
Females
Advise females of reproductive potential to use effective contraception during treatment with SUTENT and for at least 4 weeks after the last dose.
Males
Based on findings in animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception during treatment with SUTENT and for 7 weeks after the last dose.
Infertility
Based on findings in animals, SUTENT may impair male and female fertility [see Nonclinical Toxicology (13.1)].
Pediatric Use
The safety and effectiveness of SUTENT in pediatric patients have not been established. Safety and pharmacokinetics of sunitinib were assessed in an open-label study (NCT00387920) in pediatric patients 2 years to <17 years of age (n=29) with refractory solid tumors. In addition, efficacy, safety and pharmacokinetics of sunitinib was assessed in another open-label study (NCT01462695) in pediatric patients 2 years to <17 years of age (n=27) with high-grade glioma or ependymoma. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. Sunitinib was poorly tolerated in pediatric patients. The occurrence of dose-limiting cardiotoxicity prompted an amendment of the NCT00387920 study to exclude patients with previous exposure to anthracyclines or cardiac radiation. No responses were reported in patients in either of the trials.
Apparent clearance and volume of distribution normalized for BSA for sunitinib and its active major metabolite were lower in pediatrics as compared to adults.
The effect on open tibial growth plates in pediatric patients who received SUTENT has not been adequately studied. See Juvenile Animal Toxicity Data below.
Juvenile Animal Toxicity Data
Physeal dysplasia was present in cynomolgus monkeys with open growth plates treated with sunitinib for ≥3 months (3 month dosing 2, 6, 12 mg/kg/day; 8 cycles of dosing 0.3, 1.5, 6.0 mg/kg/day) at doses that were >0.4 times the combined AUC (the combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg. The no-effect level (NOEL) was 1.5 mg/kg/day in monkeys treated intermittently for 8 cycles, but was not identified in monkeys treated continuously for 3 months. In developing rats treated continuously for 3 months (1.5, 5.0, and 15.0 mg/kg) or 5 cycles (0.3, 1.5, and 6.0 mg/kg/day), bone abnormalities consisted of thickening of the epiphyseal cartilage of the femur and an increase of fracture of the tibia at doses ≥5 mg/kg (approximately 10 times the combined AUC in patients administered the RDD of 50 mg). Additionally, tooth caries were present in rats at >5 mg/kg. The incidence and severity of physeal dysplasia were dose related and reversible upon cessation of treatment; however, findings in the teeth were not. In rats, the NOEL in bones was ≤2 mg/kg/day.
Geriatric Use
Of the 7527 patients with GIST, RCC (advanced and adjuvant), or pNET who received SUTENT, 32% were 65 years and older, and 7% were 75 years and older. Patients aged 65 years of age and older had a higher incidence of Grade 3 or 4 adverse reactions (67%) than younger patients (60%).
In the GIST study, 73 (30%) of the patients who received SUTENT were 65 years and older. In the mRCC study, 152 (41%) of patients who received SUTENT were 65 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients.
In the pNET study, 22 (27%) of the patients who received SUTENT were 65 years and older. Clinical studies of SUTENT did not include sufficient numbers of patients with pNET to determine if patients 65 years of age and older respond differently than younger patients.
Hepatic Impairment
No dose adjustment is required in patients with mild or moderate (Child-Pugh Class A or B) hepatic impairment [see Clinical Pharmacology (12.3)]. SUTENT was not studied in patients with severe (Child-Pugh Class C) hepatic impairment.
Renal Impairment
No dose adjustment is recommended in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis [see Clinical Pharmacology (12.3)].
No dose adjustment is recommended for patients with end-stage renal disease (ESRD) on hemodialysis [see Clinical Pharmacology (12.3)].
None.
Hepatotoxicity
SUTENT can cause severe hepatotoxicity, resulting in liver failure or death. In the pooled safety population, liver failure occurred in <1% of patients in clinical trials. Liver failure include jaundiced, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure.
Monitor liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and bilirubin) at baseline, during each cycle, and as clinically indicated. Interrupt SUTENT for Grade 3 hepatotoxicity until resolution to Grade ≤1 or baseline, then resume SUTENT at a reduced dose.
Discontinue SUTENT in patients with Grade 4 hepatotoxicity, in patients without resolution of Grade 3 hepatotoxicity, in patients who subsequently experience severe changes in liver function tests and in patients who have other signs and symptoms of liver failure. Safety in patients with ALT or AST >2.5 × upper limit of normal (ULN) or with >5 × ULN and liver metastases has not been established.
Cardiovascular Events
Cardiovascular events, including heart failure, cardiomyopathy, myocardial ischemia, and myocardial infarction, some of which were fatal, have been reported.
In pooled safety population, 3% of patients experienced heart failure; 71% of the patients with heart failure were reported as recovered. Fatal cardiac failure was reported in <1% of patients.
In the adjuvant treatment of RCC study, 11 patients experienced Grade 2 decreased ejection fraction (left ventricular ejection fraction [LVEF] 40% to 50% and a 10% to 19% decrease from baseline). In 3 of these 11 patients, the ejection fractions arm did not return to ≥50% or baseline by the time of last measurement. No patients who received SUTENT were diagnosed with CHF.
Patients who presented with cardiac events within 12 months prior to SUTENT administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from SUTENT clinical studies. Patients with prior anthracycline use or cardiac radiation were also excluded from some studies. It is unknown whether patients with these concomitant conditions may be at a higher risk of developing left ventricular dysfunction.
Consider monitoring LVEF at baseline and periodically as clinically indicated. Carefully monitor patients for clinical signs and symptoms of congestive heart failure (CHF). Discontinue SUTENT in patients who experience clinical manifestations of CHF. Interrupt SUTENT and/or reduce the dose in patients without clinical evidence of CHF who have an ejection fraction of greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline ejection fraction was not obtained.
QT Interval Prolongation and Torsade de Pointes
SUTENT can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in <0.1% of patients.
Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with SUTENT.
Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing SUTENT [see Dosage and Administration (2.5), Drug Interactions (7.2)].
Hypertension
In the pooled safety population, 29% of patients experienced hypertension. Grade 3 hypertension was reported in 7% of patients, and Grade 4 hypertension was reported in 0.2%.
Monitor blood pressure at baseline and as clinically indicated. Initiate and/or adjust antihypertensive therapy as appropriate. In cases of Grade 3 hypertension, withhold SUTENT until resolution to Grade ≤1 or baseline, then resume SUTENT at a reduced dose. Discontinue SUTENT in patients with who develop Grade 4 hypertension.
Hemorrhagic Events and Viscus Perforation
Hemorrhagic events, some of which were fatal, have involved the gastrointestinal tract, respiratory tract, tumor, urinary tract, and brain. In the pooled safety population, 30% of patients experienced hemorrhagic events, including Grade 3 or 4 in 4.2% of patients. Epistaxis was the most common hemorrhagic event and gastrointestinal hemorrhage was the most common Grade 3–5 event.
Tumor-related hemorrhage was observed in patients treated with SUTENT. These events may occur suddenly, and in the case of pulmonary tumors, may present as severe and life-threatening hemoptysis or pulmonary hemorrhage. Pulmonary hemorrhage, some with a fatal outcome, was observed in patients treated with SUTENT for metastatic RCC, GIST, and metastatic lung cancer. SUTENT is not approved for use in patients with lung cancer.
Serious, sometimes fatal, gastrointestinal complications including gastrointestinal perforation, have been reported in patients with intra-abdominal malignancies treated with SUTENT.
Include serial complete blood counts (CBCs) and physical examinations with the clinical assessment of hemorrhagic events. Interrupt SUTENT for Grade 3 or 4 hemorrhagic events until resolution to Grade ≤1 or baseline, then resume SUTENT at a reduced dose.
Discontinue SUTENT in patients without resolution of Grade 3 or 4 hemorrhagic events.
Tumor Lysis Syndrome
Tumor Lysis Syndrome (TLS), some fatal, occurred in clinical trials and has been reported in postmarketing experience, primarily in patients with RCC or GIST. Patients generally at risk of TLS are those with high tumor burden prior to treatment. Monitor these patients for TLS and manage as appropriate.
Thrombotic Microangiopathy
Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of SUTENT as monotherapy and administered in combination with bevacizumab. SUTENT is not approved for use in combination with bevacizumab.
Discontinue SUTENT in patients developing TMA. Reversal of the effects of TMA has been observed after SUTENT was discontinued.
Proteinuria
Proteinuria and nephrotic syndrome have been reported. Some of these cases have resulted in renal failure and fatal outcomes.
Monitor patients for the development or worsening of proteinuria. Perform baseline and periodic urinalyses during treatment, with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt SUTENT and dose reduce for 24-hour urine protein of 3 or more grams. Discontinue SUTENT for patients with nephrotic syndrome or repeat episodes of 24-hour urine protein of 3 or more grams despite dose reductions. The safety of continued SUTENT treatment in patients with moderate to severe proteinuria has not been evaluated.
Dermatologic Toxicities
Severe cutaneous adverse reactions have been reported, including erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), some of which were fatal. Permanently discontinue SUTENT for these severe cutaneous adverse reactions.
Necrotizing fasciitis, including fatal cases, has been reported in patients treated with SUTENT, including of the perineum and secondary to fistula formation. Discontinue SUTENT in patients who develop necrotizing fasciitis.
Reversible Posterior Leukoencephalopathy Syndrome
Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in <1% of patients, some of which were fatal. Patients can present with hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness. Magnetic resonance imaging is necessary to confirm the diagnosis. Discontinue SUTENT in patients developing RPLS.
Thyroid Dysfunction
Hyperthyroidism, some followed by hypothyroidism, have been reported in clinical trials and through postmarketing experience of SUTENT.
Monitor thyroid function at baseline, periodically during treatment and as clinically indicated. Monitor patients closely for signs and symptoms of thyroid dysfunction, including hypothyroidism, hyperthyroidism, and thyroiditis, during treatment with SUTENT. Initiate and/or adjust therapies for thyroid dysfunction as appropriate.
Hypoglycemia
SUTENT can result in symptomatic hypoglycemia, which may lead to loss of consciousness, or require hospitalization. In the pooled safety population, hypoglycemia occurred in 2% of the patients treated with SUTENT. Hypoglycemia has occurred in clinical trials in 2% of the patients treated with SUTENT for advanced RCC (Study 3) and GIST (Study 1) (n=577) and in approximately 10% of the patients treated with SUTENT for pNET (Study 6) (n=83). For patients being treated with SUTENT for pNET, pre-existing abnormalities in glucose homeostasis were not present in all patients who experienced hypoglycemia. Reductions in blood glucose levels may be worse in patients with diabetes.
Check blood glucose levels at baseline, regularly during treatment, as clinically indicated and after discontinuation of SUTENT. In patients with diabetes, assess if antidiabetic therapies need to be adjusted to minimize the risk of hypoglycemia.
Osteonecrosis of the Jaw
Osteonecrosis of the Jaw (ONJ) occurred in patients treated with SUTENT. Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. Perform an oral examination prior to initiation of SUTENT and periodically during SUTENT therapy. Advise patients regarding good oral hygiene practices. Withhold SUTENT treatment for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold SUTENT for development of ONJ until complete resolution. The safety of resumption of SUTENT after resolution of osteonecrosis of the jaw has not been established.
Impaired Wound Healing
Impaired wound healing has been reported in patients who received SUTENT [see Adverse Reactions (6.2)].
Withhold SUTENT for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of SUTENT after resolution of wound healing complications has not been established.
Embryo-Fetal Toxicity
Based on findings from animal studies and its mechanism of action, SUTENT can cause fetal harm when administered to pregnant woman. Administration of sunitinib to pregnant rats and rabbits during the period of organogenesis resulted in teratogenicity at approximately 5.5 and 0.3 times the combined systemic exposure [combined area under the curve (AUC) of sunitinib plus its active metabolite] in patients administered the recommended daily dose (RDD) of 50 mg, respectively.
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with SUTENT and for 4 weeks following the final dose [see Use in Specific Populations (8.1, 8.3)].
The following clinically significant adverse reactions are described elsewhere in the labeling.
- •
- Hepatotoxicity [see Warnings and Precautions (5.1)]
- •
- Cardiovascular Events [see Warnings and Precautions (5.2)]
- •
- QT Interval Prolongation and Torsade de Pointes [see Warnings and Precautions (5.3)]
- •
- Hypertension [see Warnings and Precautions (5.4)]
- •
- Hemorrhagic Events [see Warnings and Precautions (5.5)]
- •
- Tumor Lysis Syndrome [see Warnings and Precautions (5.6)]
- •
- Thrombotic Microangiopathy [see Warnings and Precautions (5.7)]
- •
- Proteinuria [see Warnings and Precautions (5.8)]
- •
- Dermatologic Toxicities [see Warnings and Precautions (5.9)]
- •
- Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.10)]
- •
- Thyroid Dysfunction [see Warnings and Precautions (5.11)]
- •
- Hypoglycemia [see Warnings and Precautions (5.12)]
- •
- Osteonecrosis of the Jaw [see Warnings and Precautions (5.13)]
- •
- Impaired Wound Healing [see Warnings and Precautions (5.14)]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the Warnings and Precautions reflect exposure to SUTENT in 7527 patients with GIST, RCC (advanced and adjuvant), or pNET. In this pooled safety population, the most common adverse reactions (≥25%) were fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, and thrombocytopenia.
Gastrointestinal Stromal Tumor
The safety of SUTENT was evaluated in Study 1, a randomized, double-blind, placebo-controlled trial in which previously treated patients with GIST received SUTENT 50 mg daily on Schedule 4/2 (n=202) or placebo (n=102). Median duration of blinded study treatment was 2 cycles for patients on SUTENT (mean: 3.0; range: 1–9) and 1 cycle (mean; 1.8; range: 1–6) for patients on placebo at the time of the interim analysis.
Permanent discontinuation due to an adverse reaction occurred in 7% of patients in the SUTENT arm. Dose reductions occurred in 11% and dose interruptions occurred in 29% of patients who received SUTENT.
Table 3 summarizes the adverse reactions for Study 1.
| Adverse Reaction | GIST | |||
|---|---|---|---|---|
| SUTENT (N=202) | Placebo (N=102) | |||
| All Grades % | Grade 3–4 % | All Grades % | Grade 3–4 % | |
| Abbreviations: GIST=gastrointestinal stromal tumor; N=number of patients. | ||||
| ||||
Any Adverse Reaction | 94 | 56 | 97 | 51 |
Gastrointestinal | ||||
Diarrhea | 40 | 4 | 27 | 0 |
Mucositis/stomatitis | 29 | 1 | 18 | 2 |
Constipation | 20 | 0 | 14 | 2 |
Metabolism/Nutrition | ||||
Anorexia † | 33 | 1 | 29 | 5 |
Asthenia | 22 | 5 | 11 | 3 |
Dermatology | ||||
Skin discoloration | 30 | 0 | 23 | 0 |
Rash | 14 | 1 | 9 | 0 |
Hand-foot syndrome | 14 | 4 | 10 | 3 |
Neurology | ||||
Altered taste | 21 | 0 | 12 | 0 |
Cardiac | ||||
Hypertension | 15 | 4 | 11 | 0 |
Musculoskeletal | ||||
Myalgia/limb pain | 14 | 1 | 9 | 1 |
Other clinically relevant adverse reactions included oral pain other than mucositis/stomatitis in 6%; hair color changes in 7%; alopecia in 5% of patients who received SUTENT.
Table 4 summarizes the laboratory abnormalities in Study 1.
| Laboratory Abnormality | GIST | |||
|---|---|---|---|---|
| SUTENT (N=202) | Placebo (N=102) | |||
| All Grades * % | Grade 3–4 *, † % | All Grades * % | Grade 3–4 *, ‡ % | |
| Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GIST=gastrointestinal stromal tumor; LVEF=left ventricular ejection fraction; N=number of patients. | ||||
| ||||
Any Laboratory Abnormality | 34 | 22 | ||
Hematology | ||||
Neutrophils decreased | 53 | 10 | 4 | 0 |
Lymphocytes decreased | 38 | 0 | 16 | 0 |
Platelets decreased | 38 | 5 | 4 | 0 |
Hemoglobin decreased | 26 | 3 | 22 | 2 |
Gastrointestinal | ||||
AST/ALT increased | 39 | 2 | 23 | 1 |
Lipase increased | 25 | 10 | 17 | 7 |
Alkaline phosphatase increased | 24 | 4 | 21 | 4 |
Amylase increased | 17 | 5 | 12 | 3 |
Total bilirubin increased | 16 | 1 | 8 | 0 |
Indirect bilirubin increased | 10 | 0 | 4 | 0 |
Renal/Metabolic | ||||
Creatinine increased | 12 | 1 | 7 | 0 |
Potassium decreased | 12 | 1 | 4 | 0 |
Sodium increased | 10 | 0 | 4 | 1 |
Cardiac | ||||
Decreased LVEF | 11 | 1 | 3 | 0 |
After an interim analysis, the study was unblinded and patients on the placebo arm were given the opportunity to receive open-label SUTENT [see Clinical Studies (14.1)]. For 241 patients randomized to the SUTENT arm, including 139 who received SUTENT in both the double-blind and open-label phases, the median duration of SUTENT treatment was 6 cycles (mean: 8.5; range: 1–44). For the 255 patients who ultimately received open-label SUTENT treatment, median duration of treatment was 6 cycles (mean: 7.8; range: 1–37) from the time of the unblinding.
Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received SUTENT. Dosage interruption occurred in 46% and dose reduction occurred in 28% of patients who received SUTENT.
The most common Grade 3 or 4 adverse reactions in patients who received SUTENT in the open-label phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%).
Advanced Renal Cell Carcinoma
The safety of SUTENT was evaluated in Study 3, a double-blind, active-controlled trial in which previously untreated patients with locally advanced or metastatic RCC received SUTENT 50 mg daily on Schedule 4/2 (n=375) or interferon alfa 9 million International Units (MIU) (n=360). The median duration of treatment was 11.1 months (range: 0.4 to 46.1) for SUTENT treatment and 4.1 months (range: 0.1 to 45.6) for interferon alfa treatment.
Permanent discontinuation due to an adverse reaction occurred in 20% of patients in the SUTENT arm. Dose interruptions occurred in 54% and dose reductions occurred in 52% of patients who received SUTENT.
Table 5 summarizes the adverse reactions for Study 3.
| Adverse Reaction | Treatment-Naïve RCC | |||
|---|---|---|---|---|
| SUTENT (N=375) | Interferon Alfa (N=360) | |||
| All Grades % | Grade 3–4 † % | All Grades % | Grade 3–4 ‡ % | |
| Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. | ||||
| ||||
Any Adverse Reaction | 99 | 77 | 99 | 55 |
Gastrointestinal | ||||
Diarrhea | 66 | 10 | 21 | <1 |
Nausea | 58 | 6 | 41 | 2 |
Mucositis/stomatitis | 47 | 3 | 5 | <1 |
Vomiting | 39 | 5 | 17 | 1 |
Dyspepsia | 34 | 2 | 4 | 0 |
Abdominal pain § | 30 | 5 | 12 | 1 |
Constipation | 23 | 1 | 14 | <1 |
Dry mouth | 13 | 0 | 7 | <1 |
Oral pain | 14 | <1 | 1 | 0 |
Flatulence | 14 | 0 | 2 | 0 |
GERD/reflux esophagitis | 12 | <1 | 1 | 0 |
Glossodynia | 11 | 0 | 1 | 0 |
Hemorrhoids | 10 | 0 | 2 | 0 |
Constitutional | ||||
Fatigue | 62 | 15 | 56 | 15 |
Asthenia | 26 | 11 | 22 | 6 |
Fever | 22 | 1 | 37 | <1 |
Weight decreased | 16 | <1 | 17 | 1 |
Chills | 14 | 1 | 31 | 0 |
Chest Pain | 13 | 2 | 7 | 1 |
Influenza like illness | 5 | 0 | 15 | <1 |
Metabolism/Nutrition | ||||
Anorexia ¶ | 48 | 3 | 42 | 2 |
Neurology | ||||
Altered taste # | 47 | <1 | 15 | 0 |
Headache | 23 | 1 | 19 | 0 |
Dizziness | 11 | <1 | 14 | 1 |
Hemorrhage/Bleeding | ||||
Bleeding, all sites | 37 | 4 Þ | 10 | 1 |
Cardiac | ||||
Hypertension | 34 | 13 | 4 | <1 |
Edema peripheral | 24 | 2 | 5 | 1 |
Ejection fraction decreased | 16 | 3 | 5 | 2 |
Dermatology | ||||
Rash | 29 | 2 | 11 | <1 |
Hand-foot syndrome | 29 | 8 | 1 | 0 |
Skin discoloration/yellow skin | 25 | <1 | 0 | 0 |
Dry skin | 23 | <1 | 7 | 0 |
Hair color changes | 20 | 0 | <1 | 0 |
Alopecia | 14 | 0 | 9 | 0 |
Erythema | 12 | <1 | 1 | 0 |
Pruritus | 12 | <1 | 7 | <1 |
Musculoskeletal | ||||
Pain in extremity/limb discomfort | 40 | 5 | 30 | 2 |
Arthralgia | 30 | 3 | 19 | 1 |
Back pain | 28 | 5 | 14 | 2 |
Respiratory | ||||
Cough | 27 | 1 | 14 | <1 |
Dyspnea | 26 | 6 | 20 | 4 |
Nasopharyngitis | 14 | 0 | 2 | 0 |
Oropharyngeal pain | 14 | <1 | 2 | 0 |
Upper respiratory tract infection | 11 | <1 | 2 | 0 |
Endocrine | ||||
Hypothyroidism | 16 | 2 | 1 | 0 |
Psychiatric | ||||
Insomnia | 15 | <1 | 10 | 0 |
Depression ß | 11 | 0 | 14 | 1 |
Table 6 summarizes the laboratory abnormalities in Study 3.
| Laboratory Abnormality | Treatment-Naïve RCC | |||
|---|---|---|---|---|
| SUTENT (N=375) | Interferon Alfa (N=360) | |||
| All Grades * % | Grade 3–4 *, † % | All Grades * % | Grade 3–4 *, ‡ % | |
| Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; RCC=renal cell carcinoma. | ||||
| ||||
Hematology | ||||
Hemoglobin decreased | 79 | 8 | 69 | 5 |
Neutrophils decreased | 77 | 17 | 49 | 9 |
Platelets decreased | 68 | 9 | 24 | 1 |
Lymphocytes decreased | 68 | 18 | 68 | 26 |
Renal/Metabolic | ||||
Creatinine increased | 70 | <1 | 51 | <1 |
Creatine kinase increased | 49 | 2 | 11 | 1 |
Uric acid increased | 46 | 14 | 33 | 8 |
Calcium decreased | 42 | 1 | 40 | 1 |
Phosphorus decreased | 31 | 6 | 24 | 6 |
Albumin decreased | 28 | 1 | 20 | 0 |
Glucose increased | 23 | 6 | 15 | 6 |
Sodium decreased | 20 | 8 | 15 | 4 |
Glucose decreased | 17 | 0 | 12 | <1 |
Potassium increased | 16 | 3 | 17 | 4 |
Calcium increased | 13 | <1 | 10 | 1 |
Potassium decreased | 13 | 1 | 2 | <1 |
Sodium increased | 13 | 0 | 10 | 0 |
Gastrointestinal | ||||
AST increased | 56 | 2 | 38 | 2 |
Lipase increased | 56 | 18 | 46 | 8 |
ALT increased | 51 | 3 | 40 | 2 |
Alkaline phosphatase increased | 46 | 2 | 37 | 2 |
Amylase increased | 35 | 6 | 32 | 3 |
Total bilirubin increased | 20 | 1 | 2 | 0 |
Indirect bilirubin increased | 13 | 1 | 1 | 0 |
Long-Term Safety in RCC
The long-term safety of SUTENT in patients with metastatic RCC was analyzed across 9 completed clinical studies conducted in the first-line, bevacizumab-refractory, and cytokine-refractory treatment settings. The analysis included 5739 patients, of whom 807 (14%) were treated for at least 2 years and 365 (6%) for at least 3 years. Prolonged treatment with SUTENT did not appear to be associated with new types of adverse reactions. There appeared to be no increase in the yearly incidence of adverse reactions at later time points. Hypothyroidism increased during the second year of treatment with new cases reported up to year 4.
Adjuvant Treatment of RCC
The safety of SUTENT was evaluated in S-TRAC, a randomized, double-blind, placebo-controlled trial in which patients who had undergone nephrectomy for RCC received SUTENT 50 mg daily on Schedule 4/2 (n=306) or placebo (n=304). The median duration of treatment was 12.4 months (range: 0.13 to 14.9) for SUTENT and 12.4 months (range: 0.03 to 13.7) for placebo.
Permanent discontinuation due to an adverse reaction occurred in 28% of patients in the SUTENT arm. Adverse reactions leading to permanent discontinuation in >2% of patients include hand-foot syndrome and fatigue/asthenia. Dosing interruptions occurred in 54% and dose reductions occurred in 46% of patients who received SUTENT.
Table 7 summarizes the adverse reactions in S-TRAC.
| Adverse Reaction | Adjuvant Treatment of RCC | |||
|---|---|---|---|---|
| SUTENT (N=306) | Placebo (N=304) | |||
| All Grades % | Grade 3–4 % | All Grades % | Grade 3–4 % | |
| Abbreviations: ARs=adverse reactions; N=number of patients; RCC=renal cell carcinoma. | ||||
| ||||
Any Adverse Reaction | 99 | 60 | 88 | 15 |
Gastrointestinal | ||||
Mucositis/Stomatitis † | 61 | 6 | 15 | 0 |
Diarrhea | 57 | 4 | 22 | <1 |
Nausea | 34 | 2 | 15 | 0 |
Dyspepsia | 27 | 1 | 7 | 0 |
Abdominal pain ‡ | 25 | 2 | 9 | <1 |
Vomiting | 19 | 2 | 7 | 0 |
Constipation | 12 | 0 | 11 | 0 |
Constitutional | ||||
Fatigue/Asthenia | 57 | 8 | 34 | 2 |
Localized edema § | 18 | <1 | <1 | 0 |
Pyrexia | 12 | <1 | 6 | 0 |
Dermatology | ||||
Hand-foot syndrome | 50 | 16 | 10 | <1 |
Rash ¶ | 24 | 2 | 12 | 0 |
Hair color changes | 22 | 0 | 2 | 0 |
Skin discoloration/Yellow skin | 18 | 0 | 1 | 0 |
Dry skin | 14 | 0 | 6 | 0 |
Cardiac | ||||
Hypertension # | 39 | 8 | 14 | 1 |
Edema/Peripheral edema | 10 | <1 | 7 | 0 |
Neurology | ||||
Altered taste Þ | 38 | <1 | 6 | 0 |
Headache | 19 | <1 | 12 | 0 |
Endocrine | ||||
Hypothyroidism/TSH increased | 24 | <1 | 4 | 0 |
Hemorrhage/Bleeding | ||||
Bleeding events, all sites ß | 24 | <1 | 5 | <1 |
Metabolism/Nutrition | ||||
Anorexia/Decreased appetite | 19 | <1 | 5 | 0 |
Musculoskeletal | ||||
Pain in extremity | 15 | <1 | 7 | 0 |
Arthralgia | 11 | <1 | 10 | 0 |
Grade 4 adverse reactions in patients on SUTENT included hand-foot syndrome (1%), fatigue (<1%), abdominal pain (< 1%), stomatitis (<1%), and pyrexia (< 1%).
Grade 3–4 laboratory abnormalities that occurred in ≥2% of patients receiving SUTENT include neutropenia (13%), thrombocytopenia (5%), leukopenia (3%), lymphopenia (3%), elevated alanine aminotransferase (2%), elevated aspartate aminotransferase (2%), hyperglycemia (2%), and hyperkalemia (2%).
Advanced Pancreatic Neuroendocrine Tumors
The safety of SUTENT was evaluated in Study 6, a randomized, double-blind, placebo-controlled trial in which patients with progressive pNET received SUTENT 37.5 mg once daily (n=83) or placebo (n=82). The median number of days on treatment was 139 days (range: 13–532 days) for patients on SUTENT and 113 days (range: 1–614 days) for patients on placebo. Nineteen patients (23%) on SUTENT and 4 patients (5%) on placebo were on study for >1 year.
Permanent discontinuation due to an adverse reaction occurred in 22% in the SUTENT arm. Dose interruptions occurred in 30% and dose reductions occurred in 31% of patients who received SUTENT.
Table 8 summarizes the adverse reactions in Study 6.
| Adverse Reaction | pNET | |||
|---|---|---|---|---|
| SUTENT (N=83) | Placebo (N=82) | |||
| All Grades % | Grade 3–4 † % | All Grades % | Grade 3–4 % | |
| Abbreviations: N=number of patients; pNET=pancreatic neuroendocrine tumors. | ||||
| ||||
Any Adverse Reaction | 99 | 54 | 95 | 50 |
Gastrointestinal | ||||
Diarrhea | 59 | 5 | 39 | 2 |
Stomatitis/oral syndromes ‡ | 48 | 6 | 18 | 0 |
Nausea | 45 | 1 | 29 | 1 |
Abdominal pain § | 39 | 5 | 34 | 10 |
Vomiting | 34 | 0 | 31 | 2 |
Dyspepsia | 15 | 0 | 6 | 0 |
Constitutional | ||||
Asthenia | 34 | 5 | 27 | 4 |
Fatigue | 33 | 5 | 27 | 9 |
Weight decreased | 16 | 1 | 11 | 0 |
Dermatology | ||||
Hair color changes | 29 | 1 | 1 | 0 |
Hand-foot syndrome | 23 | 6 | 2 | 0 |
Rash | 18 | 0 | 5 | 0 |
Dry skin | 15 | 0 | 11 | 0 |
Cardiac | ||||
Hypertension | 27 | 10 | 5 | 1 |
Hemorrhage/Bleeding | ||||
Bleeding events ¶ | 22 | 0 | 10 | 4 |
Epistaxis | 21 | 1 | 5 | 0 |
Neurology | ||||
Dysgeusia | 21 | 0 | 5 | 0 |
Headache | 18 | 0 | 13 | 1 |
Psychiatric | ||||
Insomnia | 18 | 0 | 12 | 0 |
Musculoskeletal | ||||
Arthralgia | 15 | 0 | 6 | 0 |
Table 9 summarizes the laboratory abnormalities in Study 6.
| pNET | ||||
|---|---|---|---|---|
| Laboratory Abnormality | SUTENT | Placebo | ||
| All Grades * % | Grade 3–4 *, † % | All Grades * % | Grade 3–4 *, ‡ % | |
| Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; N=number of patients; pNET=pancreatic neuroendocrine tumors. | ||||
| ||||
Gastrointestinal | ||||
AST increased | 72 | 5 | 70 | 3 |
Alkaline phosphatase increased | 63 | 10 | 70 | 11 |
ALT increased | 61 | 4 | 55 | 3 |
Total bilirubin increased | 37 | 1 | 28 | 4 |
Amylase increased | 20 | 4 | 10 | 1 |
Lipase increased | 17 | 5 | 11 | 4 |
Hematology | ||||
Neutrophils decreased | 71 | 16 | 16 | 0 |
Hemoglobin decreased | 65 | 0 | 55 | 1 |
Platelets decreased | 60 | 5 | 15 | 0 |
Lymphocytes decreased | 56 | 7 | 35 | 4 |
Renal/Metabolic | ||||
Glucose increased | 71 | 12 | 78 | 18 |
Albumin decreased | 41 | 1 | 37 | 1 |
Phosphorus decreased | 36 | 7 | 22 | 5 |
Calcium decreased | 34 | 0 | 19 | 0 |
Sodium decreased | 29 | 2 | 34 | 3 |
Creatinine increased | 27 | 5 | 28 | 5 |
Glucose decreased | 22 | 2 | 15 | 4 |
Potassium decreased | 21 | 4 | 14 | 0 |
Magnesium decreased | 19 | 0 | 10 | 0 |
Potassium increased | 18 | 1 | 11 | 1 |
Venous Thromboembolic Events
In pooled safety population, 3.5% of patients experienced a venous thromboembolic event, including Grade 3–4 in 2.2% of patients.
Pancreatic Function
Pancreatitis was observed in 1 patient (1%) in the pNET study, 5 patients (1%) in the treatment-naïve RCC study, and 1 patient (<1%) in the adjuvant treatment for RCC study on SUTENT.
Postmarketing Experience
The following adverse reactions have been identified during postapproval use of SUTENT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- •
- Blood and lymphatic system disorders: hemorrhage associated with thrombocytopenia 1.
- •
- Gastrointestinal disorders: esophagitis.
- •
- Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis.
- •
- Immune system disorders: hypersensitivity reactions, including angioedema.
- •
- Infections and infestations: serious infection (with or without neutropenia) 1. The infections most commonly observed with SUTENT include respiratory, urinary tract, skin infections, and sepsis/septic shock.
- •
- Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression 1; myopathy and/or rhabdomyolysis with or without acute renal failure 1.
- •
- Renal and urinary disorders: renal impairment and/or failure 1.
- •
- Respiratory disorders: pulmonary embolism 1, pleural effusion 1.
- •
- Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive de-challenges.
- •
- Vascular disorders: arterial (including aortic) aneurysms, dissections 1, and rupture 1; arterial thromboembolic events 1. The most frequent events included cerebrovascular accident, transient ischemic attack, and cerebral infarction.
- •
- General disorders and administration site conditions: impaired wound healing.
- 1
- including some fatalities
Effect of Other Drugs on SUTENT
Strong CYP3A4 Inhibitors
Co-administration with strong CYP3A4 inhibitors may increase sunitinib plasma concentrations [see Clinical Pharmacology (12.3)]. Select an alternate concomitant medication with no or minimal enzyme inhibition potential. Consider a dose reduction for SUTENT when it is co-administered with strong CYP3A4 inhibitors [see Dosage and Administration (2.5)].
Strong CYP3A4 Inducers
Co-administration with strong CYP3A4 inducers may decrease sunitinib plasma concentrations [see Clinical Pharmacology (12.3)]. Select an alternate concomitant medication with no or minimal enzyme induction potential. Consider a dose increase for SUTENT when it must be co-administered with CYP3A4 inducers [see Dosage and Administration (2.5)].
Drugs that Prolong QT Interval
SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3), Clinical Pharmacology (12.2)]. Monitor the QT interval with ECGs more frequently in patients who require treatment with concomitant medications known to prolong the QT interval.
Sunitinib is a kinase inhibitor present in SUTENT capsules as the malate salt. Sunitinib malate is described chemically as (2S)-2-hydroxybutanedoic acid with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1). The molecular formula is C22H27FN4O2 ∙ C4H6O5 and the molecular weight is 532.6 Daltons. The chemical structure of sunitinib malate is:
Sunitinib malate is a yellow to orange powder with a pKa of 8.95. The solubility of sunitinib malate in aqueous media over the range pH 1.2 to pH 6.8 is in excess of 25 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7 is 5.2.
SUTENT (sunitinib malate) capsules are supplied as printed hard shell capsules containing 12.5 mg, 25 mg, 37.5 mg or 50 mg of sunitinib (equivalent to 16.7 mg, 33.4 mg, 50.1 mg, or 66.8 mg of sunitinib malate, respectively). The capsules contain the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, and povidone (K-25). The orange gelatin capsule shells contain titanium dioxide and red iron oxide; the caramel gelatin capsule shells contain titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide; and the yellow gelatin capsule shells contain titanium dioxide and yellow iron oxide. The white printing ink contains shellac, propylene glycol, sodium hydroxide, povidone, and titanium dioxide and the black printing ink contains shellac, propylene glycol, potassium hydroxide, and black iron oxide.
Mechanism of Action
Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.
Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRβ, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRβ- and VEGFR2-dependent tumor angiogenesis in vivo.
Pharmacodynamics
Exposure-Response Relationship
Based on population pharmacokinetic/pharmacodynamic analyses, there were relationships between changes in different pharmacodynamic endpoints (i.e., safety and efficacy endpoints) over time and sunitinib plasma exposures.
Cardiac Electrophysiology
SUTENT can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes [see Warnings and Precautions (5.3)].
Pharmacokinetics
The pharmacokinetics of sunitinib and sunitinib malate have been evaluated in healthy subjects and in patients with solid tumors.
Sunitinib AUC and Cmax increase proportionately over a dose range of 25 mg to 100 mg (0.5 to 2 times the approved RDD of 50 mg). The pharmacokinetics were similar in healthy subjects and in patients with a solid tumor, including patients with GIST and RCC. No significant changes in the pharmacokinetics of sunitinib or the primary active metabolite were observed with repeated daily administration or with repeated cycles. With repeated daily administration, sunitinib accumulates 3- to 4-fold while the primary metabolite accumulates 7- to 10-fold. Steady-state concentrations of sunitinib and its primary active metabolite are achieved within 10 to 14 days. By Day 14, combined plasma concentrations of sunitinib and its active metabolite ranged from 63 to 101 ng/mL.
Absorption
Following oral administration of sunitinib, the time to maximum plasma concentration (Tmax) ranged from 6 to 12 hours.
Effect of Food
The administration of a single dose of SUTENT 50 mg with a high-fat, high-calorie meal (consisting of approximately 150 protein calories and 500 to 600 fat calories) in healthy subjects had no clinically significant effect on SUTENT or active metabolites exposure.
Distribution
The apparent volume of distribution (Vd/F) for sunitinib is 2230 L. Binding of sunitinib and its primary active metabolite to human plasma protein in vitro is 95% and 90%, respectively, with no concentration dependence in the range of 100 to 4000 ng/mL.
Elimination
Following administration of a single oral dose in healthy subjects, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively. Sunitinib total oral clearance (CL/F) ranged from 34 to 62 L/h with an interpatient variability of 40%.
Metabolism
Sunitinib is metabolized primarily by CYP3A4 to its primary active metabolite, which is further metabolized by CYP3A4. The primary active metabolite comprises 23% to 37% of the total exposure. After a radiolabeled dose, sunitinib and its active metabolite were the major compounds identified in plasma, accounting for 92% of radioactivity.
Excretion
After a radiolabeled dose of sunitinib, approximately 61% of the dose was recovered in feces and 16% in urine.
Sunitinib and its primary active metabolite were the major compounds identified in urine and feces, representing 86% and 74% of radioactivity, respectively.
Specific Populations
No clinically significant differences in the pharmacokinetics of sunitinib or the primary active metabolite were observed based on age (18 to 84 years), body weight (34 to 168 kg), race (White, Black, or Asian), sex, Eastern Cooperative Oncology Group (ECOG) score, mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Patients with Renal Impairment
No clinically significant differences in the pharmacokinetics of sunitinib or its active metabolite were predicted or observed in patients with mild (CLcr 50 to 80 mL/min), moderate (CLcr 30 to <50 mL/min), or severe (CLcr <30 mL/min) renal impairment who are not on dialysis, compared to patients with normal renal function (CLcr >80 mL/min). Although sunitinib was not eliminated through hemodialysis, the sunitinib systemic exposure was 47% lower in patients with end stage renal disease (ESRD) on hemodialysis compared to patients with normal renal function.
Drug Interaction Studies
Clinical Studies
Effect of strong CYP3A4 inhibitors on sunitinib: Co-administration of a single SUTENT dose with ketoconazole (strong CYP3A4 inhibitor) increased the combined sunitinib and its active metabolite Cmax and AUC0–inf by 49% and 51%, respectively, in healthy subjects.
Effect of strong CYP3A4 inducers on sunitinib: Co-administration of a single SUTENT dose with rifampin (strong CYP3A4 inducer) reduced the combined sunitinib and its active metabolite Cmax and AUC0–inf by 23% and 46%, respectively in healthy subjects.
In Vitro Studies
In vitro studies in human hepatocytes and microsomes indicated that sunitinib and the primary active metabolite do not induce CYP1A2, CYP2E1, and CYP3A4/5, or inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11 at clinically relevant concentrations.
Carcinogenesis, Mutagenesis, Impairment of Fertility
The carcinogenic potential of sunitinib has been evaluated in 2 species: rasH2 transgenic mice and Sprague-Dawley rats. There were similar positive findings in both species. In rasH2 transgenic mice, gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at sunitinib daily doses of ≥25 mg/kg/day in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. Similarly, in a 2-year rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day [approximately 0.9 times the combined AUC (combined systemic exposure of sunitinib plus its active metabolite) in patients administered the RDD of 50 mg]. At the high dose of 3 mg/kg/day (approximately 8 times the combined AUC in patients administered the RDD of 50 mg), the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal gland.
Sunitinib did not cause genetic damage when tested in in vitro assays [bacterial mutation (Ames test), human lymphocyte chromosome aberration] and an in vivo rat bone marrow micronucleus test.
In a female fertility and early embryonic development study, female rats were administered oral sunitinib (0.5, 1.5, 5 mg/kg/day) for 21 days prior to mating and for 7 days after mating. Preimplantation loss was observed in females administered 5 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg). No adverse effects on fertility were observed at doses ≤1.5 mg/kg/day (approximately equal to the combined AUC in patients administered the RDD of 50 mg). In addition, effects on the female reproductive system were identified in a 3-month oral repeat-dose monkey study (2, 6, 12 mg/kg/day). Ovarian changes (decreased follicular development) were noted at 12 mg/kg/day (approximately 5 times the combined AUC in patients administered the RDD of 50 mg), while uterine changes (endometrial atrophy) were noted at ≥2 mg/kg/day (approximately 0.4 times the combined AUC in patients administered the RDD of 50 mg). With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day (approximately 0.8 times the combined AUC in patients administered the RDD of 50 mg) in a 9-month monkey study (0.3, 1.5, and 6 mg/kg/day administered daily for 28 days followed by a 14-day respite).
In a male fertility study, no reproductive effects were observed in male rats dosed with 1, 3, or 10 mg/kg/day oral sunitinib for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses ≤10 mg/kg/day (approximately ≥26 times the combined AUC in patients administered the RDD of 50 mg).
Gastrointestinal Stromal Tumor
Study 1
Study 1 (NCT#00075218) was a 2-arm, international, randomized, double-blind, placebo-controlled trial of SUTENT in patients with GIST who had disease progression during prior imatinib mesylate (imatinib) treatment or who were intolerant of imatinib. The objective was to compare time-to-tumor progression (TTP) in patients receiving SUTENT plus best supportive care versus patients receiving placebo plus best supportive care. Other objectives included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Patients were randomized (2:1) to receive either 50 mg SUTENT or placebo orally, once daily, on Schedule 4/2 until disease progression or withdrawal from the study for another reason. Treatment was unblinded at the time of disease progression. Patients randomized to placebo were then offered crossover to open-label SUTENT and patients randomized to SUTENT were permitted to continue treatment per investigator judgment.
At the time of a prespecified interim analysis, the intent-to-treat (ITT) population included 312 patients. Two hundred seven (207) patients were randomized to the SUTENT arm and 105 patients were randomized to the placebo arm. Demographics were comparable between the SUTENT and placebo groups with regard to age (69% versus 72% <65 years for SUTENT versus placebo, respectively), sex (male: 64% versus 61%), race (White: 88% both arms, Asian: 5% both arms, Black: 4% both arms, remainder not reported), and performance status (ECOG 0: 44% versus 46%, ECOG 1: 55% versus 52%, and ECOG 2: 1% versus 2%). Prior treatment included surgery (94% versus 93%) and radiotherapy (8% versus 15%). Outcome of prior imatinib treatment was also comparable between arms with intolerance (4% versus 4%), progression within 6 months of starting treatment (17% versus 16%), or progression beyond 6 months (78% versus 80%) balanced.
The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for SUTENT over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1.
| Efficacy Parameter | SUTENT (N=207) | Placebo (N=105) | p-value (log-rank test) | HR (95% CI) |
|---|---|---|---|---|
| Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; HR=hazard ratio; N=number of patients; PR=partial response. | ||||
| ||||
Time-to-tumor progression * | 27.3 | 6.4 | <0.0001 † | 0.33 |
Progression-free survival ‡ | 24.1 | 6.0 | <0.0001 | 0.33 |
Objective response rate (PR) | 6.8 | 0 | 0.006 § | |
Figure 1. Kaplan-Meier Curve of TTP in GIST Study 1 (Intent-to-Treat Population)
Abbreviations: CI=confidence interval; GIST=gastrointestinal stromal tumor; N=number of patients; TTP=time-to-tumor progression.
The final ITT population enrolled in the double-blind treatment phase of the study included 243 patients randomized to the SUTENT arm and 118 patients randomized to the placebo arm. After the primary endpoint was met at the interim analysis, the study was unblinded, and patients on the placebo arm were offered open-label SUTENT treatment. Ninety-nine (99) of the patients initially randomized to placebo crossed over to receive SUTENT in the open-label treatment phase. At the protocol specified final analysis of OS, the median OS was 72.7 weeks for the SUTENT arm and 64.9 weeks for the placebo arm [hazard ratio (HR)=0.876, 95% confidence interval (CI) (0.679, 1.129)].
Study 2
Study 2 was an open-label, multi-center, single-arm, dose-escalation study conducted in patients with GIST following progression on, or intolerance to imatinib. Following identification of the recommended regimen (50 mg once daily on Schedule 4/2), 55 patients in this study received the 50 mg dose of SUTENT on treatment Schedule 4/2. Partial responses (PR) were observed in 5 of 55 patients (9.1% PR rate; 95% CI: 3.0%, 20.0%).
Renal Cell Carcinoma
Treatment-Naïve
Study 3 (NCT#00083889) was a multi-center, international, randomized study comparing single-agent SUTENT with interferon alfa was conducted in patients with treatment-naïve RCC. The objective was to compare PFS in patients receiving SUTENT versus patients receiving interferon alfa. Other endpoints included ORR, OS, and safety. Seven hundred fifty (750) patients were randomized (1:1) to receive either 50 mg SUTENT once daily on Schedule 4/2 or to receive interferon alfa administered subcutaneously at 9 million international units (MIU) 3 times a week. Patients were treated until disease progression or withdrawal from the study.
The ITT population included 750 patients, 375 randomized to SUTENT and 375 randomized to interferon alfa. Demographics were comparable between the SUTENT and interferon alfa groups with regard to age (59% versus 67% <65 years for SUTENT versus interferon alfa, respectively), sex (male: 71% versus 72%), race (White: 94% versus 91%, Asian: 2% versus 3%, Black: 1% versus 2%, remainder not reported), and performance status (ECOG 0: 62% versus 61%, ECOG 1: 38% each arm, ECOG 2: 0 versus 1%). Prior treatment included nephrectomy (91% versus 89%) and radiotherapy (14% each arm). The most common site of metastases present at screening was the lung (78% versus 80%, respectively), followed by the lymph nodes (58% versus 53%, respectively) and bone (30% each arm); the majority of the patients had multiple (2 or more) metastatic sites at baseline (80% versus 77%, respectively).
There was a statistically significant advantage for SUTENT over interferon alfa in the endpoint of PFS (see Table 11 and Figure 2). In the prespecified stratification factors of lactate dehydrogenase (LDH) (>1.5 ULN versus ≤1.5 ULN), ECOG performance status (0 versus 1), and prior nephrectomy (yes versus no), the hazard ratio favored SUTENT over interferon alfa. The ORR was higher in the SUTENT arm (see Table 11).
| Efficacy Parameter | SUTENT (N=375) | Interferon Alfa (N=375) | p-value (log-rank test) | HR (95% CI) |
|---|---|---|---|---|
| Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; RCC=renal cell carcinoma. | ||||
| ||||
Progression-free survival * | 47.3 | 22.0 | <0.000001 † | 0.415 |
Objective response rate * | 27.5 | 5.3 | <0.001 ‡ | NA |
Figure 2. Kaplan-Meier Curve of PFS in Treatment-Naïve RCC Study 3 (Intent-to-Treat Population)
Abbreviations: CI=confidence interval; IFN-α=interferon-alfa; N=number of patients; PFS=progression-free survival; RCC=renal cell carcinoma.
At the protocol-specified final analysis of OS, the median OS was 114.6 weeks for the SUTENT arm and 94.9 weeks for the interferon alfa arm (HR=0.821; 95% CI: 0.673, 1.001). The median OS for the interferon alfa arm includes 25 patients who discontinued interferon alfa treatment because of disease progression and crossed over to treatment with SUTENT as well as 121 patients (32%) on the interferon alfa arm who received post-study cancer treatment with SUTENT.
Cytokine-Refractory
The use of single-agent SUTENT in the treatment of cytokine-refractory RCC was investigated in 2 single-arm, multi-center studies. All patients enrolled into these studies experienced failure of prior cytokine-based therapy. In Study 4 (NCT#00077974), failure of prior cytokine therapy was based on radiographic evidence of disease progression defined by response evaluation criteria in solid tumors (RECIST) or World Health Organization (WHO) criteria during or within 9 months of completion of 1 cytokine therapy treatment (interferon alfa, interleukin-2, or interferon alfa plus interleukin-2; patients who were treated with interferon alfa alone must have received treatment for at least 28 days). In Study 5 (NCT#00054886), failure of prior cytokine therapy was defined as disease progression or unacceptable treatment-related toxicity. The endpoint for both studies was ORR. Duration of response (DR) was also evaluated.
One hundred and six patients (106) were enrolled into Study 4 and 63 patients were enrolled into Study 5. Patients received 50 mg SUTENT on Schedule 4/2. Therapy was continued until the patients met withdrawal criteria or had progressive disease. The baseline age, sex, race, and ECOG performance statuses of the patients were comparable between Studies 4 and 5. Approximately 86%–94% of patients in the 2 studies were White. Men comprised 65% of the pooled population. The median age was 57 years and ranged from 24 to 87 years in the studies. All patients had an ECOG performance status <2 at the screening visit.
The baseline malignancy and prior treatment history of the patients were comparable between Studies 4 and 5. Across the 2 studies, 95% of the pooled population of patients had at least some component of clear-cell histology. All patients in Study 4 were required to have a histological clear-cell component. Most patients enrolled in the studies (97% of the pooled population) had undergone nephrectomy; prior nephrectomy was required for patients enrolled in Study 4. All patients had received 1 previous cytokine regimen. Metastatic disease present at the time of study entry included lung metastases in 81% of patients. Liver metastases were more common in Study 4 (27% versus 16% in Study 5) and bone metastases were more common in Study 5 (51% versus 25% in Study 4); 52% of patients in the pooled population had at least 3 metastatic sites. Patients with known brain metastases or leptomeningeal disease were excluded from both studies.
The ORR and DR data from Studies 4 and 5 are provided in Table 12. There were 36 PRs in Study 4 as assessed by a core radiology laboratory for an ORR of 34.0% (95% CI: 25.0%, 43.8%). There were 23 PRs in Study 5 as assessed by the investigators for an ORR of 36.5% (95% CI: 24.7%, 49.6%). The majority (>90%) of objective disease responses were observed during the first 4 cycles; the latest reported response was observed in Cycle 10. DR data from Study 4 is premature as only 9 of 36 patients (25%) responding to treatment had experienced disease progression or died at the time of the data cutoff.
| Efficacy Parameter | Study 4 (N=106) | Study 5 (N=63) |
|---|---|---|
| Abbreviations: CI=confidence interval; N=number of patients; NR=not reached; RCC=renal cell carcinoma. | ||
| ||
Objective response rate | 34.0 * | 36.5 † |
Duration of response | NR ‡ | 54 † |
Adjuvant Treatment
In the adjuvant treatment setting, SUTENT was investigated in S-TRAC (NCT#00375674), a multi-center, international, randomized, double-blind, placebo-controlled, trial in patients with high risk of recurrent RCC following nephrectomy. Patients were required to have clear cell histology and high risk of recurrence defined as ≥T3 and/or N+ tumors. Six hundred fifteen (615) patients were randomized 1:1 to receive either 50 mg SUTENT once daily on Schedule 4/2 or placebo. Patients were treated for 9 cycles (approximately 1 year), or until disease recurrence, unacceptable toxicity, or withdrawal of consent.
Demographics were generally comparable between the SUTENT and placebo arms with regard to age (median age 58 years), sex (73% male), and race (84% White, 12% Asian and 4% Other). At randomization, most patients had an ECOG performance status of 0 (74% SUTENT and 72% placebo). The remainder of the patients had an ECOG performance status of 1; 1 patient on SUTENT had a performance status of 2.
The major efficacy outcome measure was disease-free survival (DFS) in patients receiving SUTENT versus placebo as assessed by blinded independent central review (BICR). Overall survival was an additional endpoint. There was a statistically significant improvement in DFS in patients who were treated with SUTENT compared to placebo (Table 13 and Figure 3). Prespecified subgroup analyses are presented in Table 14. At the time of the DFS analysis, overall survival data were not mature, with 141/615 (23%) patient deaths.
| SUTENT N=309 | Placebo N=306 | p-value * | HR * (95% CI) | |
|---|---|---|---|---|
| Abbreviations: BICR=blinded independent central review; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; RCC=renal cell carcinoma. | ||||
| ||||
Median DFS [years (95% CI)] | 6.8 (5.8, NR) | 5.6 (3.8, 6.6) | 0.03 | 0.76 (0.59, 0.98) |
DFS Events | 113 (36.6%) | 144 (47.1%) | ||
5 Year DFS Rate | 59.3% | 51.3% | ||
| Number of Events/ Total n/N | Median DFS [years (95% CI)] | HR * (95% CI) | |||
|---|---|---|---|---|---|
| SUTENT | Placebo | SUTENT | Placebo | ||
| Abbreviations: CI=confidence interval; DFS=disease-free survival; HR=hazard ratio; N=number of patients; n=number of events; NR=not reached | |||||
| |||||
T3 Intermediate † | 35/115 | 46/112 | NR | 6.4 | 0.82 |
T3 High ‡ | 63/165 | 79/166 | 6.8 | 5.3 | 0.77 |
T4/Node Positive § | 15/29 | 19/28 | 3.5 | 1.7 | 0.62 |
Figure 3. Kaplan-Meier Curve of Disease-free Survival as Assessed by BICR (Intent-to-Treat Population)
Abbreviations: BICR=blinded independent central review; CI=confidence interval; N=number of patients.
Pancreatic Neuroendocrine Tumors
Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent SUTENT conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg SUTENT (N=86) or placebo (N=85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving SUTENT versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study.
Demographics were comparable between the SUTENT and placebo groups. Additionally, 49% of SUTENT patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of SUTENT patients received prior systemic therapy compared with 72% of placebo patients and 35% of SUTENT patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to SUTENT in a separate extension study.
As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for SUTENT over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring SUTENT was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the SUTENT arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring SUTENT over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4.
| Efficacy Parameter | SUTENT (N=86) | Placebo (N=85) | p-value | HR (95% CI) |
|---|---|---|---|---|
| Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NA=not applicable; pNET=pancreatic neuroendocrine tumors. | ||||
| ||||
Progression-free survival | 10.2 | 5.4 | 0.000146 * | 0.427 |
Objective response rate | 9.3 | 0 | 0.0066 † | NA |
Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6
Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors.
SUTENT 12.5 mg capsules are supplied as hard gelatin capsule with orange cap and orange body, printed with white ink "Pfizer" on the cap, "STN 12.5 mg" on the body:
Bottles of 28 capsules: NDC 0069-0550-38
SUTENT 25 mg capsules are supplied as hard gelatin capsule with caramel cap and orange body, printed with white ink "Pfizer" on the cap, "STN 25 mg" on the body:
Bottles of 28 capsules: NDC 0069-0770-38
SUTENT 37.5 mg capsules are supplied as hard gelatin capsule with yellow cap and yellow body, printed with black ink "Pfizer" on the cap, "STN 37.5 mg" on the body:
Bottles of 28 capsules: NDC 0069-0830-38
SUTENT 50 mg capsules are supplied as hard gelatin capsule with caramel cap and caramel body, printed with white ink "Pfizer" on the cap, "STN 50 mg" on the body:
Bottles of 28 capsules: NDC 0069-0980-38
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Mechanism of Action
Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.
Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRβ, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRβ- and VEGFR2-dependent tumor angiogenesis in vivo.